Sector News

Will buyers go after Mylan once it inverts? Don’t count on it, analyst says

December 3, 2014
Life sciences
As Mylan gears up to close a $5.3 billion deal to buy a chunk of Abbott’s generics business and shift its tax base to the Netherlands, some investors are speculating it could itself become a target for another stateside company looking for a tax inversion. But to that, Sanford Bernstein analyst Tim Anderson says they shouldn’t hold their breath.
 
The reason? Most of the company’s likely suitors don’t actually make that good a match, he wrote in a Tuesday note to clients. Take Pfizer, for example, which has been jonesing for a tax inversion since this spring’s failed play for British pharma giant AstraZeneca. Mylan will be too small to help the company complete one, Anderson notes, as foreign targets must be at least 20% of the buyer’s size.
 
And then there’s Teva, for whom the Mylan could be too large to swallow. With a market cap of $48 billion, Teva would need to make more than a couple significant divestments–like Epipen, which generates about 30% of Mylan’s profits–to afford the Pennsylvania drugmaker, whose own market cap is $22 billion, Anderson points out.
 
“Buying Mylan would mean the company will commit to a different direction than what it was apparently planning on,” he said.
 
If any interested buyers do go after Mylan, they’ll have to take heed of the company’s strategic plan to lift its share price to $73 by 2018–a 26% premium to its current price. “We do not see the board of the company accepting a lower offer,” he wrote.
 
Of course, “one should never say never about transactions,” he said, and that doesn’t mean both Pfizer and Teva won’t be pursuing other targets too–inversion or no inversion. Analysts figure Pfizer needs to make a move in the near-term, and some industry watchers think it could still come back and make another run at AZ. As for the Israeli generics behemoth, it’s been scouting for deals in the $10 billion to $15 billion range, Anderson says. Pickups could potentially help Teva toward its stated goals of widening its emerging markets footprint and becoming a biosimilars contender.
 
By Carly Helfand
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach